Literature DB >> 35025074

Colorectal Cancer Prevalence and Survival in Cuenca (Spain).

Laura Valiente González1, Ricardo de Miguel Ibáñez2, Francisco Escribano Sotos3.   

Abstract

BACKGROUND: Colorectal cancer is the most commonly diagnosed cancer type and the second cause of cancer death in Spain. The primary risk factor for colorectal cancer is age, with 90% of all diagnosed patients aged over 50 years. Prognosis mainly depends on tumour stage. AIM: Conduct a colorectal cancer prevalence and survival study in Cuenca (Spain) since there are almost no studies based on small populations. This is the first study about survival in screening of colorectal cancer carried out in hospitals in Castilla-La Mancha.
METHODS: Retrospective descriptive cohort study was performed to include patients with colorectal cancer diagnosed by colonoscopy between May 2015 and April 2016, and who were followed up for 48 months. The study considered sociodemographic and clinical data of the patients. Survival curves were estimated using the Kaplan-Meier method. The proportional hazard rate associated with age, gender, stage, and presence of metastasis was calculated using the Cox regression method.
RESULTS: Fifty-seven patients were included in the study. The mean follow-up was 45.5 months. Ten patients died during the study; in seven cases, the cause was colorectal cancer. The percentage of patients alive at a 48-month follow-up was 82.4%.
CONCLUSION: Colon cancer is a high-prevalence pathology, with adenocarcinoma being the most common histology. The results seem to indicate that it affects men more frequently, mortality rises with tumour stage at diagnosis and declines with use of chemotherapy. We present a study that could justify large-scale epidemiological studies for the regional surveillance and evolution of colorectal cancer in Spain.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Chemotherapy; Colorectal cancer; Screening; Stage; Survival

Year:  2022        PMID: 35025074     DOI: 10.1007/s12029-021-00784-x

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  13 in total

1.  The effect of diagnostic delay attributable to the healthcare system on the prognosis of colorectal cancer.

Authors:  Jesús Daniel Fernández-de Castro; Franco Baiocchi Ureta; Raquel Fernández González; Noel Pin Vieito; Joaquín Cubiella Fernández
Journal:  Gastroenterol Hepatol       Date:  2019-08-15       Impact factor: 2.102

2.  Why is colon cancer survival improving by time? A nationwide survival analysis spanning 35 years.

Authors:  Petur Snaebjornsson; Larus Jonasson; Elinborg J Olafsdottir; Nicole C T van Grieken; Pall H Moller; Asgeir Theodors; Thorvaldur Jonsson; Gerrit A Meijer; Jon G Jonasson
Journal:  Int J Cancer       Date:  2017-05-19       Impact factor: 7.396

Review 3.  Cost Effectiveness of Colorectal Cancer Screening Strategies.

Authors:  Shaan S Patel; Meredith L Kilgore
Journal:  Cancer Control       Date:  2015-04       Impact factor: 3.302

Review 4.  [The Alliance for the Prevention of Colorectal Cancer in Spain. A civil commitment to society].

Authors:  Juan Diego Morillas; Antoni Castells; Isabel Oriol; Ana Pastor; Pedro Pérez-Segura; José Manuel Echevarría; Begoña Caballero; Andrés González-Navarro; Fernando Bandrés; Enric Brullet; Antonio Iniesta; Fernando Carballo; Rosa Bouzas; Aurelio Ariza; Alfredo Ibisate; Pilar García-Alfonso; Beatriz Escudero; Silvia Camacho; Ana Fernández-Marcos; Teresa González; Enrique Quintero; Angel Lanas; Mercè Marzo; Juanjo Mascort; Monserrat Andréu; Laura Cerezo; Enrique Vázquez-Sequeiros; Josep María Borrás; Dolores Salas; Nieves Ascunce; Isabel Portillo; Mayte Herráiz; María Luisa Valle; Amalia Sotoca; Santiago Nieto; Carlos Hué; Luis Paz-Ares
Journal:  Gastroenterol Hepatol       Date:  2012-02-23       Impact factor: 2.102

5.  Colorectal cancer prognosis twenty years later.

Authors:  Luis Bujanda; Cristina Sarasqueta; Elisabeth Hijona; Lander Hijona; Angel Cosme; Ines Gil; Jose Luis Elorza; Jose I Asensio; Santiago Larburu; José M Enríquez-Navascués; Rodrigo Jover; Francesc Balaguer; Xavier Llor; Xavier Bessa; Montserrat Andreu; Artemio Paya; Antoni Castells
Journal:  World J Gastroenterol       Date:  2010-02-21       Impact factor: 5.742

6.  Cost-Effectiveness of Colorectal Cancer Screening Strategies-A Systematic Review.

Authors:  Tao Ran; Chih-Yuan Cheng; Benjamin Misselwitz; Hermann Brenner; Jasper Ubels; Michael Schlander
Journal:  Clin Gastroenterol Hepatol       Date:  2019-01-16       Impact factor: 11.382

7.  European cancer mortality predictions for the year 2018 with focus on colorectal cancer.

Authors:  M Malvezzi; G Carioli; P Bertuccio; P Boffetta; F Levi; C La Vecchia; E Negri
Journal:  Ann Oncol       Date:  2018-04-01       Impact factor: 32.976

8.  Prevalence and survival benefit of adjuvant chemotherapy in stage III colon cancer patients: Comparison of overall and age-stratified results by multivariable modeling and propensity score methodology in a population-based cohort.

Authors:  Robert B Hines; Milan Bimali; Asal M Johnson; A Rana Bayakly; Tracie C Collins
Journal:  Cancer Epidemiol       Date:  2016-08-08       Impact factor: 2.984

9.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

10.  Colon cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.

Authors:  Arica White; Djenaba Joseph; Sun Hee Rim; Christopher J Johnson; Michel P Coleman; Claudia Allemani
Journal:  Cancer       Date:  2017-12-15       Impact factor: 6.860

View more
  1 in total

1.  RIG-I Promotes Cell Viability, Colony Formation, and Glucose Metabolism and Inhibits Cell Apoptosis in Colorectal Cancer by NF-κB Signaling Pathway.

Authors:  Yangyang Liu; Shufang Ye; Yabi Zhu; Luyi Chen; Zizhen Zhang
Journal:  Dis Markers       Date:  2022-02-22       Impact factor: 3.434

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.